Helping advance oligonucleotide innovation

Oligonucleotides are giving rise to a new generation of therapeutics—and Nitto Avecia is helping lead the way. With more than 25 years’ experience in oligonucleotide development and production, we are the partner of choice for pharmaceutical innovators creating new drugs with the power to transform treatment for a wide range of diseases.

Unmatched oligonucleotide experience

Nitto Avecia was the first CMO to serve the oligonucleotide therapeutic market. Since then, we have manufactured more than 1,200 oligonucleotide sequences and developed the most extensive late-phase portfolio of any oligonucleotide CMO. This experience gives our analytical, manufacturing, and quality teams unparalleled expertise to make your oligonucleotide program a success.

End-to-end solution

In partnership with Nitto Avecia Pharma Services, Nitto Avecia is the first CMO that offers a comprehensive, end-to-end oligonucleotide solution. This offers the advantage of a single, expert partner handling the entire process—from drug substance through drug product manufacturing—with flexible solutions and consistent reliability and quality.